Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results

Key Points

• Oculis beat quarterly earnings expectations, reporting a loss of $0.20 per share versus the consensus loss estimate of $0.48. Revenue reached $0.38 million, exceeding analyst expectations of $0.22 million.
• Shares rose to $12.68 but remain well below the 12-month high of $34.47. The company reported strong liquidity, with current and quick ratios of 5.18, but continues to post significant losses and negative profitability metrics.
• Analysts maintain a generally positive outlook, with nine Buy ratings and one Sell rating, though several firms recently cut their price targets. The consensus rating is Moderate Buy, with an average target price of $38.33.

Oculis (NASDAQ:OCS - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.28, FiscalAI reports. The business had revenue of $0.38 million for the quarter, compared to analyst estimates of $0.22 million. Oculis had a negative return on equity of 45.58% and a negative net margin of 6,777.18%.

Oculis Price Performance

Oculis stock traded up $0.30 during midday trading on Friday, reaching $12.68. The company had a trading volume of 370,877 shares, compared to its average volume of 314,551. Oculis has a 12-month low of $10.52 and a 12-month high of $34.47. The firm's fifty day simple moving average is $12.17 and its 200-day simple moving average is $22.31. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. The company has a market capitalization of $735.19 million, a P/E ratio of -7.29 and a beta of 0.51.

Institutional Trading of Oculis

A number of institutional investors have recently made changes to their positions in OCS. Bank of America Corp DE raised its holdings in Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock valued at $786,000 after acquiring an additional 878 shares during the last quarter. Geode Capital Management LLC raised its position in Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock valued at $571,000 after purchasing an additional 6,384 shares during the period. Millennium Management LLC acquired a new position in Oculis in the fourth quarter valued at about $312,000. Marshall Wace LLP purchased a new position in Oculis during the second quarter worth about $393,000. Finally, Renaissance Technologies LLC purchased a new position in Oculis during the fourth quarter worth about $499,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on OCS. Needham & Company LLC decreased their target price on shares of Oculis from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Monday, June 1st. JPMorgan Chase & Co. cut their price target on Oculis from $42.00 to $23.00 and set an "overweight" rating for the company in a research note on Wednesday, June 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $26.00 price target on shares of Oculis in a report on Wednesday. Wall Street Zen upgraded Oculis from a "strong sell" rating to a "sell" rating in a research report on Saturday. Finally, Guggenheim dropped their price objective on Oculis from $75.00 to $45.00 and set a "buy" rating on the stock in a report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $38.33.

About Oculis

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source